Tripeptides, E.g., Tripeptide Thyroliberin (trh), Melanostatin (mif), Etc. Patents (Class 530/331)
-
Publication number: 20130172264Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R1,R2,R3,R4,R5 and R6 are as described herein.Type: ApplicationFiled: January 3, 2013Publication date: July 4, 2013Applicant: GENENTECH, INC.Inventor: GENENTECH, INC.
-
Publication number: 20130171085Abstract: The invention relates to novel compounds derived from amino acids of formula (I) and also to cosmetic or dermatological compositions containing them and to their use as agents for treating human perspiration in a cosmetic composition. The invention also relates to a cosmetic process for treating perspiration and possibly the body odour associated with human perspiration, especially underarm odour.Type: ApplicationFiled: June 8, 2011Publication date: July 4, 2013Applicant: L'OREALInventors: Maria Dalko, Julien Hitce
-
Publication number: 20130172242Abstract: The present invention provides novel peptides that can modulate the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and sub-types, isoforms and variants thereof). These peptides are useful as antagonists of the ghrelin receptor as well as inverse agonist, partial agonist or a combination of these activities as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, diabetes, central nervous system disorders, genetic disorders, and hyperproliferative disorders.Type: ApplicationFiled: June 16, 2011Publication date: July 4, 2013Applicants: MCGILL UNIVERSITY, THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventors: Cyril Y. Bowers, David H. Coy, Simon J. Hocart, Gloria S. Tannenbaum
-
Publication number: 20130165386Abstract: Provided is a pharmaceutical composition comprising, as an active ingredient, a quinoline or quinazoline derivative of formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate, and a solvate thereof, which is effective in the prevention and treatment of a cancer, inflammation, autoimmune diseases or neurodegenerative disorders which are induced by the overexpression of inhibitor of apoptosis proteins (IAPs).Type: ApplicationFiled: August 31, 2011Publication date: June 27, 2013Applicant: HANMI SCIENCE CO., LTDInventors: In Hwan Bae, Eun Young Byun, Hae Kyoung Ju, Ji Young Song, Seung Hyun Jung, Seung Ah Jun, Ho Seok Kim, Young Hee Jung, Mi Yon Shim, Young Gil Ahn, Maeng Sup Kim
-
Publication number: 20130165392Abstract: Small molecule, peptidic hepatocyte growth factors mimics, which act as both mimetics and antagonists, have been generated. These molecules have been shown or predicted to have therapeutic potential for numerous pathologies including dementia, neurodegenerative disease, diabetes and metabolic syndrome, cancer, and defective wound healing.Type: ApplicationFiled: February 15, 2013Publication date: June 27, 2013Applicant: WASHINGTON STATE UNIVERSITYInventor: Washington State University
-
Publication number: 20130165333Abstract: Described herein are the preparation and use of novel bromo-phosphonomethylphenylalanine amino acid derivatives (BrPmp) and BrPmp-containing peptides as specific, irreversible protein tyrosine phosphatase inhibitors, which are suitable for application in peptide synthesis. These derivatives are particularly advantageous since their synthesis is both easy and scalable, and they are suitable for peptide synthesis. The BrPmp derivatives described herein can be appropriately protected to allow for solid phase peptide synthesis (SPPS) and incorporation into peptides for preparation of protein tyrosine phosphatase inhibitors and inhibitor libraries. The peptides and peptide libraries can be used to identify new protein tyrosine phosphatase specific sequences and profile protein tyrosine phosphatase activity in cell lysates, diagnostic samples and biopsy samples.Type: ApplicationFiled: March 3, 2011Publication date: June 27, 2013Applicant: THE GOVERNORS OF THE UNIVERSITY OF ALBERTAInventors: Christopher Warren Cairo, Naresh Singh Tulsi, Alan Michael Downey
-
Publication number: 20130156819Abstract: The present invention relates to peptides or fragments thereof, which peptides bind to mesenchymal stem cells. The present invention also relates to a method for identifying, isolating, specifically selecting and/or enriching mesenchymal stem cells, wherein the peptides, or fragments thereof, are employed for specifically binding to the mesenchymal stem cells. Also, the present invention relates to the use of the peptides of the invention, or fragments thereof, and of the mesenchymal stem cells isolated with the peptides of the invention, or fragments thereof, for treating, injuries and/or degenerated bone, cartilage or tissues.Type: ApplicationFiled: December 5, 2012Publication date: June 20, 2013Applicants: Baden-Württemberg Stiftung gGmbH, Eberhard-Karls-Universit°t Tübingen Universit°tsklinikumInventors: Eberhard-Karls-Universit°t Tübingen Universit°tskl, Baden-Württemberg Stiftung gGmbH
-
Publication number: 20130144036Abstract: The present invention discloses compounds of formula I and II or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: October 22, 2012Publication date: June 6, 2013Applicant: Enanta Pharmaceuticals, Inc.Inventor: Enanta Pharmaceuticals, Inc.
-
Publication number: 20130143976Abstract: A medical device includes a substrate having at least a portion thereof functionalized with at least one reactive member and a chemotactic agent functionalized with at least one complementary reactive member, wherein the at least one reactive member and the at least one complementary reactive member are covalently bonded, adhering the chemotactic agent to the substrate.Type: ApplicationFiled: June 30, 2011Publication date: June 6, 2013Applicant: SOFRADIM PRODUCTIONInventors: Sébastien Ladet, Philippe Gravagna
-
Publication number: 20130142764Abstract: The present disclosure provides targeting peptides and vectors containing a sequence that encodes targeting peptides that deliver agents to the brain.Type: ApplicationFiled: October 15, 2012Publication date: June 6, 2013Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATIONInventor: University of Iowa Research Foundation
-
Publication number: 20130143826Abstract: The present invention discloses chemical synthesis, anti-tumor and anti-metastatic effects of a dual functional conjugate as shown by formula I. Specifically, paclitaxel or docetaxol is linked with muramyl dipeptide derivative to form a conjugate, thus dual anti-tumor and anti-metastatic effects are achieved by combination of chemotherapy and immunotherapy. The present invention also discloses that paclitaxel or docetaxol and muramyl dipeptide derivative conjugate is synthesized by combination of solid-phase and solution-phase synthesis, and said conjugate can be used in manufacture of anti-tumor medicaments as proved by reliable bioassays.Type: ApplicationFiled: May 27, 2011Publication date: June 6, 2013Inventors: Gang Liu, Nan Zhao, Yao Ma
-
Publication number: 20130137852Abstract: The present invention relates to process for preparation of novel compounds which are acting as inhibitors of dipeptidyl peptidase-IV enzyme and is depicted by the structural formula as given below: Formula VI. Which are useful in the treatment or prevention of diseases in which the dipeptidylpeptidase-IV enzyme is involved, such as diabetes and particularly type-2 diabetes.Type: ApplicationFiled: August 3, 2011Publication date: May 30, 2013Applicant: Cadila Corporate CampusInventors: Bakulesh Mafatlal Khamar, Nirav Kishorbhai Joshi, Chandan Hardhan Singh, Uday Rajaram Bapat, Bipin Dhanjibhai Gadhiya, Nirav Sureshbhai Sagar, Indravadan Ambalal Modi
-
Patent number: 8450456Abstract: The present invention concerns a peptide of the general formula (I): R1-(AA)n-X1—X2—X3-Pro-X4—X5—X7-(AA)p-R2, capable of activating the synthesis of proteins of the family of aquaporins. The present invention also concerns a cosmetic, nutraceutical or pharmaceutical composition, comprising a peptide of general formula (I) as active principle. The invention also relates to the use of this new active principle in a cosmetic or nutraceutical composition, intended to improve the moisturizing and the barrier function of the epidermis and intended to stimulate cutaneous regeneration. The invention also relates to the use of this new active principle to realize a pharmaceutical composition, and in particular a dermatological composition, intended to regulate and/or stimulate the activity of the aquaporins and to thus treat the pathological dryness of the skin or mucosa.Type: GrantFiled: December 17, 2008Date of Patent: May 28, 2013Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Publication number: 20130129671Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.Type: ApplicationFiled: May 23, 2012Publication date: May 23, 2013Inventors: Li-Qiang Sun, Paul Michael Scola
-
Publication number: 20130131311Abstract: Improved methods of native chemical ligation are provided. The methods involve reacting a thioacid (e.g. a peptide thioacid) with an aziridinyl compound (e.g. an aziridinyl peptide) under mild conditions without the use of protecting groups, and without requiring that a cysteine residue be present in the ligation product. Initial coupling of the thioacid and the aziridinyl compound yields a ligation product which contains an aziridinyl ring. Subsequent opening of the aziridinyl ring (e.g. via a nucleophilic attack) produces a linearized and modified ligation product.Type: ApplicationFiled: November 13, 2012Publication date: May 23, 2013Applicant: WASHINGTON STATE UNIVERSITYInventor: Washington State University
-
Publication number: 20130129753Abstract: The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.Type: ApplicationFiled: November 7, 2012Publication date: May 23, 2013Applicant: PFIZER INC.Inventor: PFIZER INC.
-
Patent number: 8445636Abstract: The invention provides lipophilic conjugates comprising a peptide coupled to a fatty acid, the peptide comprising at least two positively charged amino acid residues, said peptide after conjugation to the fatty acid possessing antibacterial, antifungal, and/or anticancer activity higher than prior to conjugation. The lipophilic conjugates are suitable for treatment of infections caused by pathogenic organisms such as bacteria and fungi. The lipophilic conjugates are also suitable for sanitation, as disinfectants, or for food preservation.Type: GrantFiled: January 11, 2010Date of Patent: May 21, 2013Assignee: Yeda Research & Development Co. Ltd.Inventors: Yechiel Shai, Dorit Avrahami
-
Publication number: 20130123167Abstract: Disclosed are a novel therapeutic agent and a novel prophylactic agent for atherosclerosis, a blood cholesterol level-lowering agent, and a functional food or a food for specified health uses effective for the inhibition and/or prevention of aging of blood vessels or inflammation in blood vessels. Specifically disclosed are an inhibitor of the progression of atherosclerosis, a prophylactic agent for atherosclerosis, a blood cholesterol level-lowering agent, and a functional food and a food for specified health uses both effective for the inhibition and/or prevention of aging of blood vessels or inflammation in blood vessels, each of which comprises, as an active ingredient, a hydrolysis product of a collagen comprising at least one collagen tripeptide Gly-X-Y [wherein Gly-X-Y represents an amino acid sequence; and X and Y independently represent an amino acid residue other than Gly].Type: ApplicationFiled: March 11, 2010Publication date: May 16, 2013Applicants: Kanazawa Medical University, Jellice Co., Ltd.Inventors: Shogo Katsuda, Lihua Tang, Yasuo Sakai
-
Publication number: 20130116407Abstract: The invention relates to conjugates of macromolecular carriers and drugs comprising linkers that release the drug or a prodrug through rate-controlled beta-elimination, and methods of making and using the conjugates.Type: ApplicationFiled: May 5, 2011Publication date: May 9, 2013Inventors: Gary Ashley, Daniel V. Santi
-
Publication number: 20130116138Abstract: Described herein are small peptide domains and consensus sequences that bind small target molecules of industrial importance, e.g., metals such as nickel, ? carotene, and isoflavones such as genistein. Also described are fusion proteins containing such binding domains fused to proteins or to peptide domains like GST or GBD that bind other ligands and can be used to immobilize the target binding domain on a support. One class of fusion proteins that is useful in industrial settings are fusions that contain concatemers of target binding domains, which increases the binding equivalents per molecule.Type: ApplicationFiled: January 28, 2011Publication date: May 9, 2013Applicants: Archer-Daniels-Midland Company, Iowa State University Research Foundation, Inc.Inventors: Thomas P. Binder, Aragula Gururaj Rao, Yasufumi Yamamoto, Paul Hanke
-
Publication number: 20130115190Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.Type: ApplicationFiled: April 30, 2012Publication date: May 9, 2013Inventors: Sheldon Hiebert, Ramkumar Rajamani, Li-Qiang Sun, Eric Mull, Eric P. Gillis, Michael S. Bowsher, Qian Zhao, Nicholas A. Meanwell, Kishore V. Renduchintala, Kandhasamy Sarkunam, Pulicharla Nagalakshmi, P. V. K. Suresh Babu, Paul Michael Scola
-
Patent number: 8431684Abstract: This invention relates to a novel process for synthesizing the product ibodutant shown in the figure below, consisting of a small number of high-yield steps involving reagents and solvents with low environmental impact, characterized by the coupling of two portions, compounds (3) and (4), one of which (3) is synthesized by coupling of 6-methyl-2-benzo[b]thiophenecarboxylic acid (1) with 1-amino-alpha-alpha-cyclopentan carboxylic acid and subsequent cyclization with oxazolone, while the other, compound (4), is obtained from suitable highly selective functionalizations of 4-aminomethylpiperidine (2).Type: GrantFiled: May 11, 2010Date of Patent: April 30, 2013Assignee: Malesci Istituto Farmacobiologico S.p.A.Inventors: Fabrizio Bonaccorsi, Valentina Fedi, Danilo Giannotti
-
Publication number: 20130102527Abstract: The present invention is an inhibitor of the trypsin-like ?2/?2i sites of the proteasome. The inhibitor is characterized as being a peptide-based epoxyketone or vinyl sulfone that contains an arginine or 4-aminomethylene-L-phenylalanine at the C-terminus (i.e., at the P1 position). Methods for using the inhibitor to inhibit the activity of the ?2/?2i site of a proteasome and treat a proteasome-mediated disease or condition are also described.Type: ApplicationFiled: December 21, 2012Publication date: April 25, 2013Applicants: LEIDEN UNIVERSITY, TRUSTEES OF DARTMOUTH COLLEGEInventors: Trustees Of Dartmouth College, Leiden University
-
Patent number: 8426179Abstract: Peptides and conjugates thereof comprising one or more bioactive agents which can be coupled to a tissue via a transglutaminase and related methods.Type: GrantFiled: September 2, 2008Date of Patent: April 23, 2013Assignee: Northwestern UniversityInventors: Phillip B. Messersmith, Marsha Ritter-Jones
-
Publication number: 20130095122Abstract: The present invention relates to peptides and antibodies which bind to melanoma inhibitory activity protein and the uses of such peptides and antibodies. The invention also relates to nucleic acids coding for such peptides or antibodies. The invention also relates to pharmaceutical compositions comprising such peptides or antibodies or such nucleic acids. The present invention also relates to small molecule compounds which bind to melanoma inhibitory activity protein and to uses of such small molecule compounds. Moreover, the present invention also relates to a method of preventing dimerization and/or aggregation of melanoma inhibitory activity (MIA) protein. The invention is based on the identification of the relevant sites of interaction of the MIA protein with the inhibitory peptides/antibodies.Type: ApplicationFiled: March 17, 2011Publication date: April 18, 2013Inventors: Anja Katrin Bosserhoff, Burkhard König, Alexander Riechers, Jennifer Schmidt
-
Publication number: 20130096074Abstract: Disclosed is a protein hydrolysate having DPP-IV inhibiting activity, the hydrolysate being enriched in peptides having a length of 2-8 amino acids comprising at least one proline residue, an isolated peptide derivable from such a protein hydrolysate, or a mixture thereof, and the use of such protein hydrolysate or isolated peptide for the manufacture of a medicament, food supplement, beverage or food product for prophylaxis and/or treatment of a DPP-IV mediated condition, in particular chosen from the group of obesity, type 2 diabetes mellitus and an immunological disorder.Type: ApplicationFiled: September 14, 2012Publication date: April 18, 2013Inventor: Jan-Willem Pieter BOOTS
-
Patent number: 8420778Abstract: The invention relates to compounds and to the cosmetically acceptable salts thereof, which correspond to general formula (I), wherein: R1 represents H, —C(O)—R6, —SO2—R6 or —C(O)—XR6; R2 and R4, independent of one another, represent (CH2)n—NH2 or (CH2)3—NHC(NH)NH2; n equals 1 4; R3 represents linear or branched C1-C4 alkyl that is optionally substituted by hydroxy; R5 and R6, independent of one another, represent hydrogen, optionally substituted (C1-C24)alkyl, optionally substituted C2-C24 alkenyl, optionally substituted phenyl, optionally substituted phenyl-C1-C4 alkyl or 9-fluorenyl-methyl; X represents oxygen (—O—) or NH—; or XR5 with X?O also represents the esters of a-tocopherol, tocotrienol or retinol, with the provision that R1 and R5 do not represent hydrogen and X does not represent oxygen at the same time. The invention also relates to the production of the compounds of general formula (I) and to a cosmetically active composition that contains at least one compound of formula (I).Type: GrantFiled: November 24, 2010Date of Patent: April 16, 2013Assignee: DSM IP Assets B.V.Inventors: Hugo Ziegler, Marc Heidl, Dominik Imfeld
-
Patent number: 8420144Abstract: The present invention encompasses a method for screening for a kokumi-imparting substance by using the calcium receptor activity as an index, a composition containing a kokumi-imparting substance obtained by the screening method, a method for producing food or drink imparted with kokumi, and food or drink imparted with kokumi.Type: GrantFiled: May 16, 2008Date of Patent: April 16, 2013Assignee: Ajinomoto Co., Inc.Inventors: Yuzuru Eto, Yusuke Amino
-
Patent number: 8404646Abstract: The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2 a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.Type: GrantFiled: September 28, 2011Date of Patent: March 26, 2013Assignees: Cornell Research Foundation, Inc., Institut de Recherches Cliniques de MontrealInventors: Peter W. Schiller, Hazel H. Szeto, Kesheng Zhao
-
Publication number: 20130072431Abstract: Compounds and compositions comprising a B-type natriuretic signal peptide fragment agent, and methods of use thereof, are provided for the treatment or prevention of cardiovascular diseases, disorders, and conditions.Type: ApplicationFiled: August 17, 2012Publication date: March 21, 2013Applicant: Otago Innovation LimitedInventors: Christopher Joseph PEMBERTON, Arthur Mark Richards, Christopher John Charles, Maithri Siriwardena
-
Publication number: 20130072422Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.Type: ApplicationFiled: March 1, 2011Publication date: March 21, 2013Inventors: Kevin D. Shenk, Francesco Paralati, Mark K. Bennett
-
Patent number: 8399403Abstract: The present disclosure provides drug-ligand conjugates that are potent cytotoxins, wherein the drug is linked to the ligand through either a peptidyl, hydrazine, or disulfide linker. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.Type: GrantFiled: November 2, 2009Date of Patent: March 19, 2013Assignee: Medarex, Inc.Inventors: Sharon E. Boyd, Liang Chen, Sanjeev Gangwar, Vincent Guerlavais, Kilian Horgan, Zhi-Hong Li, Bilal Sufi
-
Patent number: 8399417Abstract: A low-fat food containing an amino acid or a peptide which is able to activate a calcium receptor, examples of which include ?-Glu-X-Gly, ?-Glu-Val-Y, ?-Glu-Ala, ?-Glu-Gly, ?-Glu-Cys, ?-Glu-Met, ?-Glu-Thr, ?-Glu-Val, ?-Glu-Orn, Asp-Gly, Cys-Gly, Cys-Met, Glu-Cys, Gly-Cys, Leu-Asp, D-Cys, ?-Glu-Met(O), ?-Glu-?-Glu-Val, ?-Glu-Val-NH2, ?-Glu-Val-ol, ?-Glu-Ser, ?-Glu-Tau, ?-Glu-Cys(S-Me)(O), ?-Glu-Leu, ?-Glu-Ile, ?-Glu-t-Leu, ?-Glu-Cys(S-Me), etc, wherein X and Y are an amino acid or an amino acid derivative.Type: GrantFiled: November 6, 2009Date of Patent: March 19, 2013Assignee: Ajinomoto Co., Inc.Inventors: Hiroaki Nagasaki, Naohiro Miyamura, Yuzuru Eto
-
Patent number: 8399612Abstract: A process comprising substitution of an acceptor molecule comprising a group —XC(O)— wherein X is O, S, or NR8, where R8 is C1-6 alkyl, C6-12 aryl or hydrogen, with a nucleophile, wherein the acceptor molecule is cyclised such that said nucleophilic substitution at —XC(O)— occurs without racemization, is provided. This process has particular application for the production of a peptide by extension from the activated carboxy-terminus of an acyl amino acid residue without epimerization.Type: GrantFiled: July 20, 2011Date of Patent: March 19, 2013Assignee: University of ReadingInventors: Laurence M. Harwood, Ran Yan
-
Publication number: 20130065827Abstract: The invention relates to crystalline peptide keto epoxide compounds, methods of their preparation, and related pharmaceutical compositions.Type: ApplicationFiled: April 6, 2011Publication date: March 14, 2013Inventor: Pasit Phiasivongsa
-
Publication number: 20130065308Abstract: The invention provides a cationic lipid comprising: (i) one head group, comprising one or more amino acids, in which at least one amino acid has a side chain that comprises a cationic moiety or a cationic precursor; (ii) a linking moiety of formula (5): —(HNR5)2NC(O)R3C(O)—??(5), wherein: each R5 is independently an optionally substituted C1-4 alkylene moiety; and R3 is an optionally substituted alkylene or alkenylene moiety; and (iii) two lipophilic moieties, wherein the head group and each of the lipophilic moieties are connected to the linking moiety through amide linkages.Type: ApplicationFiled: May 17, 2011Publication date: March 14, 2013Applicant: The University Court of the University of EdinburghInventors: Asier Unciti-Broceta, Aleksandra Liberska, Mark Bradley
-
Publication number: 20130065248Abstract: The invention provides a method of preparing a sirtuin complex. The invention also provides a method of detecting a sirtuin in a sample comprising use of the aforesaid sirtuin complex.Type: ApplicationFiled: May 18, 2011Publication date: March 14, 2013Applicant: CORNELL UNIVERSITYInventors: Anthony A. SAUVE, Yana CEN
-
Patent number: 8394922Abstract: Antiproliferative compounds having a structure represented by formula (II), where n, R1, R2, R3, R4, and R5 are as defined herein, can be used to treat tumors, optionally when conjugated to a ligand such as an antibody:Type: GrantFiled: July 29, 2010Date of Patent: March 12, 2013Assignee: Medarex, Inc.Inventors: Heng Cheng, Qiang Cong, Sanjeev Gangwar
-
Patent number: 8394769Abstract: The present invention provides an anti-hypertensive agent. The anti-hypertensive agent of the present invention contains, as an active ingredient, at least one peptide selected from the group consisting of peptides originally derived from globin proteolysate, each of which consists of one of the following amino acid sequences (1) to (6), or a globin proteolysate containing at least one of the peptides: (1) Val-Val-Tyr-Pro (SEQ ID: NO. 1); (2) Trp-Gly-Lys-Val-Asn (SEQ ID: NO. 2); (3) Trp-Gly-Lys-Val (SEQ ID: NO. 3); (4) Trp-Gly-Lys (SEQ ID: NO. 4); (5) Ala-Ala-Trp-Gly-Lys (SEQ ID: NO. 5); and (6) Phe-Glu-Ser (SEQ ID: NO. 6).Type: GrantFiled: August 7, 2008Date of Patent: March 12, 2013Assignee: MG Pharma Inc.Inventors: Kyoichi Kagawa, Chizuko Fukuhama, Hiroaki Fujino, Junnei Hidasa
-
Publication number: 20130060006Abstract: The present invention pertains to the use of certain flavour enhancing compounds obtainable from an Allium species. In one embodiment, seeds from chives, leeks, ramson and other onions are used for conveying strong kokumi flavour enhancing effects on food products without imparting an onion or garlic-like off taste. These flavour enhancing compounds are also useful for the preparation of Amadori products, which are also used as kokumi flavour enhancing compounds.Type: ApplicationFiled: November 7, 2012Publication date: March 7, 2013Applicant: PEPSICO, INC.Inventor: PEPSICO, INC.
-
Patent number: 8383595Abstract: A composition for promoting lacrimal secretion which can be used safely and effectively in the lacrimal secretion promoting therapy, not in the conventional supplemental therapy of lacrimal fluid components is provided. The composition for promoting lacrimal secretion comprising a peptide derivative represented by the formula (I): and a contact lens which retains and/or contains the composition are provided.Type: GrantFiled: June 15, 2009Date of Patent: February 26, 2013Assignees: Kinki University, Fuso Pharmaceutical Industries, Ltd.Inventors: Atsufumi Kawabata, Hiroyuki Nishikawa, Yoshiko Kawai
-
Patent number: 8377871Abstract: Novel dendrimeric peptide compounds are disclosed that have a formula represented by the following formula I: The compounds demonstrate antimicrobial activity and may be prepared as pharmaceutical compositions and used for the prevention and treatment of a variety of conditions in mammals including humans where microbial invasion is involved. The present peptides are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent to resistance provoked by standard antibiotics.Type: GrantFiled: March 4, 2011Date of Patent: February 19, 2013Assignee: New York University School of MedicineInventors: Neville Robert Kallenbach, Anne W. Young, Zhigang Liu, Chunhui Zhou
-
Publication number: 20130035470Abstract: Provided is a novel crystal of oxidized glutathione hexahydrate. Crystal of oxidized glutathione hexahydrate is produced by cooling an aqueous solution containing oxidized glutathione to 15° C. or lower to precipitate a crystal of oxidized glutathione hexahydrate.Type: ApplicationFiled: April 21, 2011Publication date: February 7, 2013Applicant: Kyowa Hakko Bio Co., Ltd.Inventors: Ken Kimura, Kenta Fukumoto, Hiroshi Tanaka
-
Publication number: 20130035297Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.Type: ApplicationFiled: October 5, 2012Publication date: February 7, 2013Applicant: ONYX THERAPEUTICS, INC.Inventor: Onyx therapeutics, Inc.
-
Publication number: 20130029960Abstract: The combined use—whether by adsorption or covalent linkage—of Melatonin adjacent any bone implant or graft, preferably any calcium- and oxide-containing artificial bone graft material, and more preferably a calcium aluminate composition. Alternatively, the bone graft or implant material may be used as a scaffold for tissue engineering.Type: ApplicationFiled: January 10, 2011Publication date: January 31, 2013Inventors: Paula A. Witt-Enderby, Kenneth McGowan, James Rutkowski, Ellen S. Gawalt, Rachelle Palchesko
-
Publication number: 20130018172Abstract: Compositions comprising certain tripeptides which are capable of binding a metal in a square planar orientation, a square pyramidal orientation, or both, are disclosed in processes for modulating tagged peptides or proteins. Such compositions and processes may be used for site-specific chiral inversion of amino acids, site-specific peptide cleavage, and protein purification, among other uses.Type: ApplicationFiled: January 13, 2012Publication date: January 17, 2013Applicants: Echogen, Inc., University of KansasInventors: Jennifer Ann Stowell Laurence, Mary Elizabeth Krause, Timothy A. Jackson, George Laurence
-
Bioactive peptides identified in enzymatic hydrolyzates of milk caseins and method of obtaining same
Patent number: 8354502Abstract: The invention relates to the production of bioactive products that are derived from milk proteins for the production of bioactive milk products derived from milk proteins, particularly caseins. The 16 inventive peptides can be obtained chemically, biotechnologically or by means of enzymatic treatment from proteins containing same and give rise to peptides with an antimicrobial activity, an in vitro angiotensin converter inhibitor activity and/or antihypertensive activity and/or antioxidant activity. Said nutraceutical products are suitable for use in the food and pharmaceutical industries, both in the form of a hydrolyzate or bioactive peptides.Type: GrantFiled: June 8, 2006Date of Patent: January 15, 2013Assignee: Consejo Superior de Investigaciones CientificasInventors: Isidra Recio Sanchez, Ana Quiros Del Bosque, Blanca Hernandez Ledesma, JoséAngel Gomez Ruiz, Marta Miguel Castro, Maria Lourdes Amigo Garrido, Ivan Lopez Exposito, Maria Mercedes Ramos Gonzalez, Amaya Aleixandre De Artiñano, Mar Contreras Gómez -
Publication number: 20130011465Abstract: The present invention includes methods of making and methods of using peptidomimetics compositions that mimic ?-helical BH3 sequences in cells. The peptidomimetics can be used to mimic ?-helical BH3 sequences and kill cancer cells.Type: ApplicationFiled: July 26, 2012Publication date: January 10, 2013Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventor: Jung-Mo Ahn
-
Publication number: 20130012686Abstract: Cosmetic composition which can be applied topically, comprising at least one compound of the general formula (I) in which R1 is H, C1-C20-alkyl, cycloalkyl or ary1-C1-C4-alkyl, n is 1-4, X is —O—, —NH— or —NR2— and R2H or C1-C20-alkyl; and at least one compound corresponding to the above formula (I) but in which XR1 with X having the possible meaning of —NH— is the residue of an alpha-amino acid; use of these compounds and of the composition for stimulating the synthesis of the proteins of the basement membrane; and also both those compounds of the formula (I) in which X is —NR2— and both R1 and R2 are different from H, and the compounds corresponding to formula (I) but in which XR1 with X having the possible meaning of —NH— is the residue of an alpha-amino acid, as such.Type: ApplicationFiled: September 13, 2012Publication date: January 10, 2013Applicant: DSM IP ASSETS B.V.Inventors: Hugo ZIEGLER, Dominik IMFELD, Martin STOCKLI, Marc HEIDL
-
Publication number: 20130011419Abstract: Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same.Type: ApplicationFiled: July 5, 2012Publication date: January 10, 2013Applicant: ImmunoGen, INC.Inventors: Ravi V.J. Chari, Robert Yongxin Zhao, Yelena Kovtun, Rajeeva Singh, Wayne Charles Widdison